Pharma
“Medicine is the restoration of discordant elements; sickness is the discord of the elements infused into the living body.” - Leonardo da Vinci
Targeting Cellular Senescence: A New Frontier in Combating Cancer and Age-Related Diseases
In the realm of cellular biology, senescence has emerged as a pivotal process influencing both the progression of cancer and the onset of age-related diseases. Defined as a state where cells cease to divide but remain metabolically active, senescence acts as a double-edged sword. Key life sciences companies are pinning pipeline hopes in cracking this.
Navigating the New Frontier: The First Abridged Complaint under the 2024 ABPI Code
In the ever-evolving landscape of pharmaceutical marketing, the industry faces a delicate balance between informing the public and adhering to strict regulations. This challenge was thrust into the spotlight with the recent case of CSL Seqirus and the alleged promotion of their prescription-only Flucelvax Influenza vaccine on the social media platform LinkedIn.
Stability Oracle: A Powerful Tool for Engineering Stable Proteins
In the rapidly evolving world of biotechnology, the ability to engineer proteins with enhanced stability is a critical challenge. Computational methods that can accurately predict how amino acid mutations will impact a protein's thermodynamic stability could revolutionize the protein engineering process. Enter Stability Oracle, a new deep learning framework that outperforms state-of-the-art methods in predicting thermodynamically stabilizing protein mutations
A New Era in US Schizophrenia Treatment: The FDA Approval of COBENFY
In a significant development for the field of neuropsychiatry, the U.S. Food and Drug Administration (FDA) has granted approval for COBENFY™ (xanomeline and trospium chloride), marking the introduction of the first new pharmacological approach to treating schizophrenia in decades
The Rise and Fall of Oxbryta: A Cautionary Tale in Sickle Cell Disease Treatment
The landscape of medical treatments for chronic illnesses is often marked by innovation, hope, and occasionally, disappointment. One such instance is the recent announcement by Pfizer to withdraw its sickle cell disease treatment, Oxbryta (voxelotor), from all markets where it was approved
The Evolving ABPI Code: Strengthening Ethical Standards in the Pharmaceutical Industry?
In the rapidly evolving landscape of the pharmaceutical industry, does the updated 2024 ABPI (Association of the British Pharmaceutical Industry) Code of Practice represent a significant step forward in raising the bar for ethical and transparent practices?
Blockchain Revolutionizing the Pharmaceutical Industry: Ensuring Transparency, Security and Efficiency
Blockchain technology has emerged as a game-changer in various sectors, and the pharmaceutical industry is no exception. With its decentralized and transparent nature, blockchain holds tremendous potential to revolutionize drug development, supply chain management, clinical trials, and patient data security
The UK’s Prescription for the Future?
The Life Sciences sector now finds itself facing intensifying global competition, with other nations aggressively courting the industry's prized assets and expertise. Meanwhile, the National Health Service (NHS) has grappled with the dual challenge of constrained budgets and the rising costs of newer, more innovative medicines
The Importance of Accurate and Balanced Promotional Claims: Lessons from the PMCPA Trelegy Case
In the highly competitive pharmaceutical industry, companies must carefully navigate the complex regulatory landscape when promoting their products. A recent case ruling by the Prescription Medicines Code of Practice Authority (PMCPA) highlights the importance of ensuring promotional claims are accurate, balanced and supported by robust evidence.
The Promise of CAR T-Cells: Progress and Challenges in Cancer Immunotherapy
Over a decade since the first clinical trials began, long-term follow-up data have affirmed CAR T-cells’ ability to induce durable remissions in certain patients. However, the therapy also faces challenges, as not all treated cancers respond equally well and toxicity remains a concern. Ongoing research aims to optimize various aspects of CAR T-cell treatment to improve outcomes on a broader scale.
A New Purpose for an Old Drug
Researchers at Creighton University may have discovered a new use for the antiviral Oseltamivir (Tamiflu) that could help many more people at risk of hearing impairment.
- Physicists uncover hidden order in the quantum...on April, 2025 at 3:38 pm
A recent study has unraveled some of the secrets concealed within the entangled web of quantum systems.
- AI model for thyroid cancer diagnosis, with over...on April, 2025 at 3:38 pm
An interdisciplinary research team has unveiled the world's first artificial intelligence (AI) model designed to classify both the cancer stage and risk category of thyroid cancer, achieving impressive accuracy exceeding 90%. This innovative AI model promises to significantly cut frontline […]
- Hidden mechanisms in next-generation AI memory...on April, 2025 at 3:37 pm
As artificial intelligence (AI) continues to advance, researchers have identified a breakthrough that could make AI technologies faster and more efficient.
- Affordable hydrogen fuel production using surface...on April, 2025 at 3:37 pm
Researchers found a strategy to create catalysts that make the production of hydrogen for clean fuel more efficient and affordable.
- Global survey highlights the challenges of...on April, 2025 at 3:37 pm
A recent global survey of 156 institutions reveals strong interest in VR-haptic technology for dental training, yet significant barriers impede widespread adoption.
After 11 years, Boston Dynamics has said goodbye to its humanoid robot ATLAS HD. The robotics company says it’s time for ATLAS to “kick back and relax” in retirement, letting the new all electric ATLAS take over. This video was shared to remember ATLAS HD’s great moments and those not so great.
Header Banner: AZT the development name for zidovudine was the first drug launched to treat HIV. It was used in high doses and as monotherapy, causing horrendous side effects and resistance in the HIV virus. In the subsequent 30 years clinical trials has led to the development of single tablet, once daily regimens to treat HIV with limited side effects. Now a two pill combination called Truvada can be given to individuals to prevent the risk of acquiring HIV (shown in the DarkDrug logo).
